Dr. Mikhail Blagosklonny has made a career of fighting the ever present cancer that has afflicted humanity since the first person drew breath. Currently, Dr. Blagosklonny is a professor of Oncology at the Rosewell Park Cancer Institute in Buffalo, New York, and editor-in-chief for Oncotarget, where he has done incredible work and research concerning aging.He is renowned for discovering another usage of Rapamycin, a drug traditionally used to prevent the body’s rejection of organ transplants: increasing a common human’s lifespan. It has obviously been used to treat cancer, but it can be used in countless other ways to halt the onset of aging complications every human has ever experienced. Besides preventing a patients organs from rejecting a foreign organ, Rapamycin, also known as Sirolimus, is great for treating patients with hemolytic-uremic syndrome, where your kidneys fail, you’re anemic and your platelet count is low.
Rapamycin prevents the transplanted kidney, essential for survival, from contracting the disease. Rapamycin also treats a wordy lung disease called Lymphangioleiomyomatosis; Rapamycin keeps it from growing and spreading, making it easier to treat. A major medical advancement Rapamycin permits is a quality treatment of cancer; it can promote tumor regression and boosts your immuno-response to the tumor. As the list continues, it becomes clear that Rapamycin is an important find; from Alzheimer’s and Muscular Dystrophy, to LSE, TSC and Facial angiofibromas. But Dr. Blagoskonny is hard at work researching how it can increase the longevity of a person, having tested Rapamycin on mice with tuberculosis. He is set to test it on the Mamoset monkey next.As one might see, Dr. Mikhail Blagosklonny is passionate in his work with oncology.
He believes that medical research can be applied to increase the lives of humans world wide, connecting it to his field of oncology as well as the subject of aging. He is a researcher, professor and philanthropist, and is intent on changing the face of oncology, from the treat-the-symptom mindset to the treat-the-disease one. He continues to conduct his research, his heart driving his Samaritan’s work, while also inspiring the students he teaches and his peers, influencing the medical profession from the floor up.He is digging deep to find a cure for cancer, but not on the beaten path of the rest of his colleagues; he is working hard to find a cure that is not nearly as excruciating or financially burden-some as the so-called cures that have been developed up until this point. He seeks to lead the way in this path, and hopes that others in his field will take up the task so that, one day, a treatment for cancer can be easy and inexpensive, brightening the future of humanity and the health of our posterity.
Over the course of his career in medicine, Dr. Mikhail Blagosklonny has come a long way in his research. Dr. Mikhail Blagosklonny has been recognized on many occasions by his peers and by institutions. The fields of research for Dr. Mikhail Blagosklonny are anti-aging and oncology. Dr. Mikhail Blagosklonny has dedicated his career to the pursuit of a cure both for cancer and aging. During his research, Dr. Mikhail Blagosklonny has even found a bridge between the two subjects as he became an advocate for using a cancer treatment drug as a way to slow down the aging process as well. The drug is called Repamycin, and it employs TOR signaling. While views on the matter are of mixed nature, the concept has been gaining supporters over the past couple of years.
Dr. Mikhail Blagosklonny is a Russian scientist. He studied in Russia and then he moved to the United States of America to seek realization and embark upon his career of research. While in Russia, Dr. Mikhail Blagosklonny attended a renowned institution located in St. Petersburg. The city is the second largest in Russia, and it is also the home of many highly esteemed schools and higher academic establishments such as the First Pavlov State Medical University where Dr. Mikhail Blagosklonny had studied. Dr. Mikhail Blagosklonny graduated with a major in the field of Internal Science. He received a Ph. D. in oncology from the establishment as well as an M. D and to know more click here
Dr. Mikhail Blagosklonny took up a position in New York City. He worked as a teacher of internal medicine at the colleoverge of New York Medical College. After some years, Dr. Mikhail Blagosklonny received a promotion. He started occupying the position of professor of oncology at another institution – the Ordway Research Institute. Dr. Mikhail Blagosklonny did research there from 2002 up until 2009. In pursuit of a better place for research, Dr. Mikhail Blagosklonny moved on to his current place – the Roswell Park Cancer Institute is the one. Dr. Mikhail Blagosklonny has dedicated himself to conducting his research with very few limitations the since 2009. The Roswell Park Cancer Institute is one of the most advanced institutions in the fight against cancer in the United States of America.
While Dr. Mikhail Blagosklonny is hugely dedicated to his studies on oncology and biogerontology, he is also contributing through his works as an editor. Dr. Mikhail Blagosklonny is a part of the editing team of three medical journals, Cell Cycle, Aging, and Oncotarget as well. He has been working with some of his colleagues from the Roswell Park cancer institute. Dr. Mikhail Blagosklonny does not only do peer reviews and editing, but he has also done a great deal of writing. He has written and published about a hundred papers so far.
To know more click here